Column Group L P 的 Form 4 申報
NGM Biopharmaceuticals Inc（NGM），2022/10/27 申報
- 申報編號
- 0000899243-22-034352
- 申報時間
- 2022/10/27 18:50 ET
- 交易日
- 2022/10/25-10/26
- 申報延遲
- 2 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 2 筆非衍生性交易。公開市場買進合計 $59.5 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Column Group L PCIK 0001347769 | 董事、持股 10% 以上大股東 |
| Column Group II, LPCIK 0001600420 | 持股 10% 以上大股東 |
| Svennilson PeterCIK 0001606074 | 持股 10% 以上大股東 |
| Kutzkey TimCIK 0001614186 | 持股 10% 以上大股東 |
| Column Group II GP, LPCIK 0001645333 | 持股 10% 以上大股東 |
| Column Group Management LPCIK 0001645340 | 持股 10% 以上大股東 |
| Ponoi Capital, LPCIK 0001707230 | 持股 10% 以上大股東 |
| Ponoi Management, LLCCIK 0001720702 | 持股 10% 以上大股東 |
| Ponoi Capital II, LPCIK 0001732601 | 持股 10% 以上大股東 |
| Ponoi II Management, LLCCIK 0001746488 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.705 to $4.80, inclusive. The Reporting Persons undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.795 to $4.95, inclusive. The Reporting Persons undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 3 to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
備註
Due to SEC restrictions on the number of reporting owners, this is Form 1 of 3.